China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

British pharmaceutical company GlaxoSmithKline on Wednesday said its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

South Korean pharmaceutical and biotech companies are presenting their latest Alzheimer’s research at the world’s largest ...

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

"Uveal Melanoma Market Insight, Epidemiology and Market Forecast - 2034"The uveal melanoma treatment market is experiencing ...

With the stock's last traded price at Rs 3,081, GlaxoSmithKline Pharmaceuticals has experienced a notable decline, positioning it among the top losers on the Nifty Midcap 150 index.